Eisai Abstract #69438: Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects This Phase 1 study was an open-label, parallel-group study conducted in healthy ...
This Phase 1 study was an open-label, parallel-group study conducted in healthy subjects: 30 subjects were randomized into a 10 mg/kg intravenous (IV) dose group and 29 subjects (5 of which were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback